All News

eular

ICYMI: SLE: advances to achieve deep B-cell depletion

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

The race is on for the first chimeric antigen receptor (CAR)-based therapy to be approved for the treatment of systemic lupus erythematosus. Its main principle is to induce deep B-cell depletion, with the hope to reset the B-cell aberrant immunity for a sustained clinical remission. At EULAR 2025 in Barcelona, several advances of CAR-based therapies will be presented.

Read Article
pills-384846_640%20%281%29.jpg

ICYMI: Should Lupus Nephritis Receive PJP Prophylaxis?

d Jack Cush, MD

A current review article suggests that the need for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in patients with systemic lupus erythematosus (SLE) and lupus nephritis will need to be individualized based on therapies and risk factors.

Read Article
guidelines.recommendations.jpg

ICYMI: Consensus Against Interventional Injections for Chronic Spinal Pain

d Jack Cush, MD

BMJ has published a clinical practice guideline resulting from the work of an international, multidisciplinary panel addressing chronic spine pain (≥3 months duration) not associated with cancer or inflammatory arthropathy. This is a chronic (not acute) spine pain guideline.

Read Article
Puzzle pieces

ICYMI: Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

d Mrinalini Dey, MD

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic options for patients with autoimmune ILDs.

Read Article
cancer.cross_.jpg

ICYMI: Channeling Bias and Cancer Risk with Biologic or Targeted Synthetic DMARDs

d Jack Cush, MD

A retrospective US administrative claims cohort study of RA patients on tumor necrosis factor inhibitors (TNFis), non-TNFi biologics, or Janus kinase inhibitors (JAKis) found a statistically significantly higher risk of incident cancer in patients receiving rituximab, abatacept, or JAKis (compared with TNFis).

Read Article
ICYMI: SLE: advances to achieve deep B-cell depletion The race is on for the first CAR-based therapy to be approved for the treatment of SLE. Its main principle is to induce deep B-cell depletion, with the hope to reset the B-cell aberrant immunity for a sustained clinical https://t.co/GohN0noESS
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Consensus Against Interventional Injections for Chronic Spinal Pain BMJ has published a clinical practice guideline resulting from the work of an international, multidisciplinary panel addressing chronic spine pain (≥3 months duration) not associated with cancer or https://t.co/tLdTFuQ5EY
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Should Lupus Nephritis Receive PJP Prophylaxis? A current review article suggests that the need for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in patients with systemic lupus erythematosus (SLE) and lupus nephritis will need to be individualized based on https://t.co/6zlPvYdeFf
Dr. John Cush RheumNow ( View Tweet)
🎩REGENCY: Obinutuzumab + standard therapy improved renal outcomes in #lupus nephritis across all tested response definitions (REGENCY, BLISS-LN, AURORA-1). Week 76 CRR consistently 13–16% higher vs placebo. Results hold despite variable thresholds. @RheumNow #EULAR2025 #OP0006

Dr. John Cush RheumNow ( View Tweet)

What happens in pre-RA when you stop #abatacept after 1 yr Rx At 6 yrs approx 60% on #Placebo V 50% who initially got #ABA Prolonged damped effect of development of #RA NNT for 1 yr is ~10 with a range as low as 6 #EULAR2025 @RheumNow @eular_org Abst#OP0004 https://t.co/eCXEWQhvWM
Dr. John Cush RheumNow ( View Tweet)
Early intensive therapy in PsA. STAMP RCT in early PsA: •ACR50 at 3mo: 43% (early secukinumab) vs 22% (SoC) •MDA at 3mo: 48% vs 25% •PASI90 at 3mo: 60% vs 22% By 12months: outcomes similar, but early secukinumab led to faster control and fewer therapy escalations. https://t.co/Mn0uW3cckf
Dr. John Cush RheumNow ( View Tweet)
POSTER HALL PRESENTATION: Sponsored by AbbVie Medical Affairs + Health Impact. 🔍Real-world outcomes in patients with RA remaining on first-line TNFi 📽️See Dr. Charles-Schoeman discuss subsequent outcomes in patients who did or did not achieve response at 3 or 6 months https://t.co/f4XLrrdich
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD CTDs and ILD represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD https://t.co/4UQ7Kgef4K
Dr. John Cush RheumNow ( View Tweet)
ICYMI: ACP: Best Practice Advice on Cannabis or Cannabinoids Use for Chronic Noncancer Pain The American College of Physicians published a best practice advisory on cannabis or cannabinoids in the Annals of Internal Medicine. https://t.co/mQI2g4W4hX https://t.co/BhfQtI792M

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Channeling Bias and Cancer Risk with Biologic or Targeted Synthetic DMARDs A retrospective US administrative claims cohort study of Rheumatoid arthritis (RA) patients on tumor necrosis factor inhibitors (TNFis), non-TNFi biologics, or Janus kinase inhibitors (JAKis) https://t.co/fYwvog09R5
Dr. John Cush RheumNow ( View Tweet)
Can IL-17F signalling be modulated by treatment with TNFi? In PsA pts non responders to previous TNFi, there was increased expression of IL17F-related gene signature. Suggesting a potential mechanism for the consistent level of clinical response observed with BKZ. Abstract https://t.co/6r59MWZAE1
Dr. John Cush RheumNow ( View Tweet)
"Education is not the learning of facts, but the training of the mind to think." - A. Einstein "Education is not the learning of facts, but the training of the mind to think." - Malcolm X Education is knowing what to do when you dont know what to do https://t.co/5CF4g78OEH
Dr. John Cush RheumNow ( View Tweet)
Secukinumab fails in GCA phase 3 RCT. Novartis announced top-line results from the GCAptAIN study evaluating secukinumab in adults with newly diagnosed or relapsing GCA. In a steroid taper RCT, the endpoint was sustained remission at Wk 52 compared to placebo https://t.co/JuMDPvznCn
Dr. John Cush RheumNow ( View Tweet)
Case series of 22 PsA pts treats w/ combination bioDMARDs & JAKi,TYK2i or APR IL17i + JAKi 10.5 PY = 1 mild infectious stomatitis IL23i + JAKi 3.7 PY = no AE IL-17i + TYK2i 8.5 PY = 2 mild upper respiratory infections IL-23i + TYK2i 8.3 PY = 2 mild URIs, 1 folliculitis TNFi + https://t.co/hxhTxmJpbN
Dr. John Cush RheumNow ( View Tweet)
First FcRn inhibitor in #IIM: In #ALKIVIA, SC efgartigimod PH20 improved TIS vs placebo at 24wks (50.45 vs 35.65, p=0.0004), with faster time to TIS≥20 (30 vs 71.5d) & TIS≥40 (113d vs NE). More major responders too (TIS>60: 34% vs 9.5%). #EULAR2025 #OP0002 https://t.co/ulxtL1NX2Y
Dr. John Cush RheumNow ( View Tweet)
×